Lonza operates 30+ pharmaceutical and biotechnology manufacturing facilities across five continents, producing active pharmaceutical ingredients and biologics under contract for drug developers. Founded in 1897 in Switzerland, the company employs approximately 19,000 people supporting development and commercial-scale manufacturing for pharmaceutical, biotech, and nutrition clients. The CDMO model requires maintaining validated processes across multiple sites while adapting to client-specific requirements and regulatory frameworks.
Manufacturing operations integrate industrial control systems and operational technology to manage batch production, environmental controls, and process monitoring across clean rooms and bioreactors. Sites implement lean manufacturing principles to optimize yield and cycle times while maintaining GMP compliance. The company's tech stack includes SIEM tools for monitoring industrial control systems and LBMS platforms for laboratory operations, reflecting the intersection of IT security requirements and regulated manufacturing environments.
Scale challenges include coordinating globally distributed teams, maintaining process consistency across geographically dispersed facilities, and managing the integration of legacy systems with newer automation platforms. The organization has adopted a unified operational strategy to standardize approaches across its manufacturing network while accommodating site-specific constraints and client protocol variations.